Biomimetic nanoparticle-driven strategies for targeted drug delivery in glioblastoma

Abstract Glioblastoma (GBM), the most prevalent primary brain tumor in adults, remains highly challenging due to its invasive nature, limited treatment effectiveness, and short median survival durations. Standard of care includes surgery, radiation, chemotherapy, and tumor treating fields; however, there has been little improvement in survival rates. Biomimetic nanoparticles (NPs), coated with cell membranes and endogenous components, have immense potential for improving chemotherapy in GBM, by imitating cellular architecture and eluding immune clearance. With more individualized and efficient drug delivery, immunotherapeutic approaches and biomimetic NPs may increase patient survival rates. This article summarizes the main research on biomimetic NPs for GBM therapy, focusing on the classification, mechanisms, advantages, and challenges, along with the advancements in the development of GBM vaccines.